The effect of burosumab on intact and C-terminal FGF23 measurements.
OBJECTIVE: To investigate the effect of CRYSVITA® (burosumab-twza) on FGF23 measurements in an intact and a C-terminal immunoassay.
METHODS: An intact serum FGF23 (MedFrontier) and a C-terminal plasma FGF23 assay (Immutopics) were used. Serum/plasma pools were spiked to span the burosumab therapeutic range (1.4-11.3 μg/ml) and FGF23 recovery was assessed. Patient serum and plasma samples obtained pre and post-burosumab treatment were evaluated on both assays and compared with corresponding phosphorus measurements RESULTS: Spiking burosumab (1.4-11.3 μg/ml) into sample pools resulted in a dose-dependent negative analytical interference on intact FGF23 measurements and no significant interference for C-terminal FGF23 measurements. However, more than a 500-fold median increase (post- vs. pre-burosumab administration) in in vivo FGF23 concentrations were observed by both assays.
CONCLUSIONS: Therapeutic concentrations of burosumab result in a negative analytical interference of the intact, but not the C-terminal FGF23 immunoassay. Despite this in vitro analytical interference in the intact assay, relatively large elevations of both intact FGF23 and C-terminal FGF23 measurements were observed in vivo following burosumab administration. Following burosumab administration, FGF23 measurements must be interpreted within the clinical context of the patient and other relevant biomarker results.
SUMMARY: This article describes a negative analytical interference by burosumab in an intact FGF23 immunoassay. The recovery of C-terminal FGF23 is not significantly affected by the presence of burosumab. In vivo, both assays demonstrate extreme FGF23 elevations in the presence of the drug. Furthermore, the measurement of FGF23 blocked by burosumab is not clinically useful regarding hypophosphataemia.
Humans; Fibroblast Growth Factors; Antibodies, Monoclonal, Humanized; Biomarkers; Biological Assay; Familial Hypophosphatemic Rickets
X-linked hypophosphatemic rickets; burosumab; chemiluminescent enzyme immunoassay (CLEIA); enzyme-linked immunosorbent assay (ELISA); fibroblast growth factor 23; interferences; tumour induced osteomalacia
Ashrafzadeh-Kian SL, Ito N, Srivastava T, et al. The effect of burosumab on intact and C-terminal FGF23 measurements. Clin Endocrinol (Oxf). 2023;99(2):152-157. doi:10.1111/cen.14832